Ouattara E, Danel C, Moh R, Gabillard D, Peytavin G, Konan R
J Int AIDS Soc. 2013; 16:18059.
PMID: 23639243
PMC: 3643089.
DOI: 10.7448/IAS.16.1.18059.
Dallas S, Read S, King S, Koren G, Bendayan R
Can J Infect Dis. 2007; 11(5):254-8.
PMID: 18159298
PMC: 2094773.
DOI: 10.1155/2000/640718.
Hsiung G
Clin Diagn Virol. 1995; 3(Suppl 1):1-81.
PMID: 15566822
PMC: 7135423.
DOI: 10.1016/0928-0197(95)80003-4.
Bhana N, Ormrod D, Perry C, Figgitt D
Paediatr Drugs. 2002; 4(8):515-53.
PMID: 12126455
DOI: 10.2165/00128072-200204080-00004.
Fayz S, Inaba T
Antimicrob Agents Chemother. 1998; 42(7):1654-8.
PMID: 9660999
PMC: 105661.
DOI: 10.1128/AAC.42.7.1654.
Systemic antifungal agents. Drug interactions of clinical significance.
Albengres E, Le Louet H, Tillement J
Drug Saf. 1998; 18(2):83-97.
PMID: 9512916
DOI: 10.2165/00002018-199818020-00001.
Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
Van Harken D, Pei J, Wagner J, Pike I
Antimicrob Agents Chemother. 1997; 41(11):2480-3.
PMID: 9371353
PMC: 164148.
DOI: 10.1128/AAC.41.11.2480.
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.
Hoetelmans R, Burger D, Meenhorst P, Beijnen J
Clin Pharmacokinet. 1996; 30(4):314-27.
PMID: 8983861
DOI: 10.2165/00003088-199630040-00004.
Absence of effect of trimethoprim-sulfamethoxazole on pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus.
Canas E, Pachon J, Castillo J, Viciana P, Cisneros J, Jimenez-Mejias M
Antimicrob Agents Chemother. 1996; 40(1):230-3.
PMID: 8787912
PMC: 163089.
DOI: 10.1128/AAC.40.1.230.
Drug interactions between prescribed and over-the-counter medication.
Honig P, Gillespie B
Drug Saf. 1995; 13(5):296-303.
PMID: 8785017
DOI: 10.2165/00002018-199513050-00003.
Drug interactions with antiviral drugs.
Taburet A, Singlas E
Clin Pharmacokinet. 1996; 30(5):385-401.
PMID: 8743337
DOI: 10.2165/00003088-199630050-00005.
Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes.
Sampol E, Lacarelle B, Rajaonarison J, Catalin J, Durand A
Br J Clin Pharmacol. 1995; 40(1):83-6.
PMID: 8527274
PMC: 1365033.
DOI: 10.1111/j.1365-2125.1995.tb04540.x.
Pharmacokinetic drug interactions with antimicrobial agents.
Gillum J, Israel D, Polk R
Clin Pharmacokinet. 1993; 25(6):450-82.
PMID: 8119047
DOI: 10.2165/00003088-199325060-00005.
Adverse effects and drug interactions of clinical importance with antiviral drugs.
Morris D
Drug Saf. 1994; 10(4):281-91.
PMID: 8018300
DOI: 10.2165/00002018-199410040-00002.
Pharmacokinetic-pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs.
Brouwers J, de Smet P
Clin Pharmacokinet. 1994; 27(6):462-85.
PMID: 7882636
DOI: 10.2165/00003088-199427060-00005.
Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
Wilde M, Langtry H
Drugs. 1993; 46(3):515-578.
PMID: 7693435
DOI: 10.2165/00003495-199346030-00010.
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
Stretcher B
Clin Pharmacokinet. 1995; 29(1):46-65.
PMID: 7586898
DOI: 10.2165/00003088-199529010-00006.
Drug interactions with zidovudine phosphorylation in vitro.
Hoggard P, Veal G, Wild M, Barry M, Back D
Antimicrob Agents Chemother. 1995; 39(6):1376-8.
PMID: 7574535
PMC: 162746.
DOI: 10.1128/AAC.39.6.1376.
